Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (GB:0LIF)
LSE:0LIF
RESEARCH TOOLSreports
Ultragenyx Pharmaceutical (0LIF) Share Price & Analysis
0 Followers
0LIF Stock Chart & Stats
Day’s Range$44.08 - $44.75
52-Week Range― - ―
Previous Close$44.22
Volume250.00
Average Volume (3M)N/A
Market Cap
$3.57B
Enterprise Value$2.99B
Total Cash (Recent Filing)$577.21M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 02, 2024EPS Estimate
-$1.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding82,335,687
10 Day Avg. Volume49
30 Day Avg. Volume160
Standard Deviation0.20
R-Squared0.20
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)56.10
Price to Sales (P/S)113.66
Price to Cash Flow (P/CF)-10.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.04
Enterprise Value/Gross Profit6.90
Enterprise Value/Ebitda-9.41
Forecast
1Y Price Target
$92.33Price Target Upside106.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Ultragenyx Pharmaceutical News
Bulls Say, Bears Say
Bulls Say
Market SentimentWith several upcoming catalysts, analysts view RARE shares favorably; reiterate Outperform and $98 PT on RARE.
Product EfficacyGTX-102 shows efficacy that appears to grow with treatment duration and has shown clinically meaningful improvements.
Regulatory MilestoneRARE is expected to meet with the FDA to seek pivotal trial design alignment, which could be a major step forward for GTX-102.
Bears Say
Drug Safety ConcernsNew events of radiculopathy have emerged, raising safety concerns and likely increasing investor scrutiny.
Financial PerformanceCrysvita sales of $375-400M (below consensus $476M)
Regulatory RisksRisks include clinical trial failures, failure to secure regulatory approval, and potential funding inadequacies.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.09% Other Institutional Investors
99.91% Public Companies and
Individual Investors
0LIF FAQ
What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Currently, no data Available
What is Ultragenyx Pharmaceutical’s market cap?
Currently, no data Available
When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
Ultragenyx Pharmaceutical’s upcoming earnings report date is May 02, 2024 which is in 12 days.
How were Ultragenyx Pharmaceutical’s earnings last quarter?
Ultragenyx Pharmaceutical released its earnings results on Feb 15, 2024. The company reported -$1.52 earnings per share for the quarter, beating the consensus estimate of -$1.707 by $0.187.
Is Ultragenyx Pharmaceutical overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends.
What is Ultragenyx Pharmaceutical’s EPS estimate?
Ultragenyx Pharmaceutical’s EPS estimate is -$1.76.
How many shares outstanding does Ultragenyx Pharmaceutical have?
Currently, no data Available
What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
Ultragenyx Pharmaceutical reported an EPS of -$1.52 in its last earnings report, beating expectations of -$1.707. Following the earnings report the stock price went up 4.264%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
Among the largest hedge funds holding Ultragenyx Pharmaceutical’s share is Sands Capital Management LLC. It holds Ultragenyx Pharmaceutical’s shares valued at 197M.
---
Ultragenyx Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$92.33 (106.32% Upside)
$92.33 (106.32% Upside)
Blogger Sentiment
Neutral
GB:0LIF Sentiment 50%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.24%
12-Months-Change
Fundamentals
Return on Equity
-193.23%
Trailing 12-Months
Asset Growth
-3.52%
Trailing 12-Months
Company Description
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
---
0LIF Company Deck
---
0LIF Earnings Call
Q4 2024
0:00 / 0:00
---
0LIF Stock 12 Months Forecast
Average Price Target
$92.33
▲(106.32% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Agios Pharma
―
Sarepta Therapeutics
―
Bluebird Bio
―
Crispr Therapeutics AG
―
Best Analysts Covering 0LIF
1 Year
1 Year Success Rate
10/17 ratings generated profit
1 Year Average Return
+1.12%
reiterated a buy rating 6 days ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +1.12% per trade.
---